ストックスクリーナーアプリを入手
14.54
1.25%
0.18
前日終値:
$14.36
開ける：
$14.28
24時間の取引高:
48,556
Relative Volume:
0.54
時価総額：
$412.96M
収益：
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.292
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
-9.41%
1か月 パフォーマンス:
-19.27%
6か月 パフォーマンス:
-14.47%
1年 パフォーマンス:
-25.44%
1日の値動き範囲:
$14.06
$15.10
1週間の範囲:
$14.06
$16.62
52週間の値動き範囲:
$11.66
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
301-348-8698
住所
7495 NEW HORIZON WAY, FREDERICK
RNAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
14.54 | 412.96M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-08-06 | 開始されました | TD Cowen | Buy |
| 2024-07-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 開始されました | Oppenheimer | Outperform |
| 2024-05-24 | 開始されました | Mizuho | Buy |
| 2024-04-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-23 | 開始されました | Leerink Partners | Outperform |
| 2023-08-18 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 繰り返されました | Needham | Buy |
| 2022-06-06 | 開始されました | SVB Leerink | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-01-26 | アップグレード | Mizuho | Neutral → Buy |
| 2020-10-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-10-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | ダウングレード | Stifel | Buy → Hold |
| 2020-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2020-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 開始されました | William Blair | Outperform |
| 2018-06-27 | 開始されました | Janney | Buy |
| 2017-03-30 | 繰り返されました | UBS | Buy |
すべてを表示
Cartesian Therapeutics Inc (RNAC) 最新ニュース
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo Finance
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com
Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - Simply Wall St
Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada
Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - Simply Wall St
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks
Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks
Cartesian Therapeutics Inc. (RNAC) reports earnings - Quartz
Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year - TipRanks
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics, Inc. SEC 10-K Report - TradingView
Cartesian's $214M War Chest Powers Breakthrough Myasthenia Gravis Treatment into Phase 3 - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by Rhumbline Advisers - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Target Price from Analysts - Defense World
New York State Common Retirement Fund Sells 1,200 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
Inside Cartesian's Latest Executive Compensation Package: Key Details Revealed - StockTitan
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Cartesian Therapeutics Advances Descartes-08 in Clinical Trials - TipRanks
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - Defense World
Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Major mRNA Cell Therapy Player Sets Ambitious 3-Conference Roadshow: Key Dates Inside - StockTitan
Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Analysts - Defense World
Leerink Partnrs Issues Optimistic Estimate for RNAC Earnings - Defense World
RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World
Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire
Cartesian Therapeutics Secures FDA SPA Agreement For Phase 3 AURORA Trial - Nasdaq
Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times
Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
Cartesian Therapeutics Inc (RNAC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
| SPRINGER TIMOTHY A | Director |
Jan 13 '25 |
Buy |
17.35 |
16,945 |
293,958 |
8,527,440 |
| SPRINGER TIMOTHY A | Director |
Jan 14 '25 |
Buy |
18.00 |
4,022 |
72,396 |
8,531,462 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 10 '25 |
Option Exercise |
3.23 |
9,000 |
29,070 |
62,490 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 06 '25 |
Sale |
16.83 |
2,458 |
41,374 |
62,258 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 03 '25 |
Sale |
16.72 |
2,417 |
40,417 |
64,716 |
| Miljkovic Milos | Chief Medical Officer |
Jan 06 '25 |
Sale |
16.83 |
948 |
15,957 |
35,393 |
| Miljkovic Milos | Chief Medical Officer |
Jan 03 '25 |
Sale |
16.72 |
932 |
15,585 |
36,341 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 06 '25 |
Sale |
16.83 |
1,286 |
21,646 |
53,490 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):